Cargando…
Metformin Use in Diabetes Prior to Hospitalization: Effects on Mortality in Covid-19
Objective: Although type 2 diabetes mellitus (T2DM) has been reported as a risk factor for coronavirus disease 2019 (COVID-19), the effect of pharmacologic agents used to treat T2DM, such as metformin, on COVID-19 outcomes remains unclear. Metformin increases the expression of angiotensin converting...
Autores principales: | Li, Jinghong, Wei, Qi, Li, Willis X, McCowen, Karen C, Xiong, Wei, Liu, Jiao, Jiang, Wenlijun, Marin, Traci, Thomas, Robert L, He, Ming, Gongol, Brendan, Hepokoski, Mark, Yuan, Jason X-J, Shyy, John Y-J, Xiong, Nian, Malhotra, Atul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834011/ https://www.ncbi.nlm.nih.gov/pubmed/33471718 http://dx.doi.org/10.4158/EP-2020-0466 |
Ejemplares similares
-
Inpatient Use of Metformin and Acarbose Is Associated with Reduced Mortality of COVID-19 Patients with Type 2 Diabetes Mellitus
por: Li, Willis, et al.
Publicado: (2021) -
Inpatient use of metformin and acarbose is associated with reduced mortality of COVID‐19 patients with type 2 diabetes mellitus
por: Li, Jinghong, et al.
Publicado: (2021) -
ACE2, Metformin, and COVID-19
por: Malhotra, Atul, et al.
Publicado: (2020) -
Cardiovascular Protective Effect of Metformin and Telmisartan: Reduction of PARP1 Activity via the AMPK-PARP1 Cascade
por: Shang, Fenqing, et al.
Publicado: (2016) -
Abstract #1176119: Development of New Onset, Protracted Hyperglycemia Triggered by COVID-19 Vaccination with Ultimate Resolution in an Individual without Prior Dysglycemia
por: Gerwer, Johanna, et al.
Publicado: (2022)